Vivalytic Powered by Randox Biochip Technology: Upper and Lower Respiratory Tract Testing

Home - Biosciences

Vivalytic Powered by Randox Biochip Technology: Upper and Lower Respiratory Tract Testing

News       About Us        Randox Biosciences

15 November 2019

 

Vivalytic Powered by Randox Biochip Technology: Upper and Lower Respiratory Tract Testing  

Vivalytic will revolutionise the way laboratories and healthcare professionals access molecular diagnostics.  A result of a collaboration between Bosch – providing innovative strength – and Randox Laboratories – dedicated to improving global healthcare – Vivalytic is the new innovative testing platform.  It’s the perfect fit for any laboratory, with numerous benefits to enhance testing capabilities.

The Vivalytic is a fully-automated, cartridge-based platform capable of both Hi-Plex and Lo-Plex testing.  Vivalytic cartridges are compact, utilising micro-fluidics to enable simple and accurate diagnostic testing.  Hi-Plex tests utilise Randox patented Biochip Technology, enabling end-point qualitative PCR and providing multiple test results from each sample.  Lo-Plex tests are based on a variety of detection methods including real-time qualitative PCR and melting curve analysis.  Nucleic acid extraction, PCR amplification followed by a suite of detection methods are combined in a truly revolutionary platform.  Manual preparation, cold chain reagents and the use of multiple devices are no longer required.

Vivalytic is the perfect fit for a healthcare professional in a point of care setting to a laboratory, which can implement the Vivalytic Up – modular and expandable testing system for higher throughput.

Benefits include:

  • Fully Automated Platform
  • Protected System
  • Direct and Clear Results
  • Hygienic and Space Saving

Vivalytic Test Menu

Vivalytic offers the most comprehensive multiplex screening test for infectious diseases including respiratory, genitourinary and hospital acquired infections; simultaneously detecting both viral and bacterial infections (please see figure 1.).

Respiratory Tract Infection Array Sexually Transmitted Infection Array Hospital Acquired Infections
Bacterial Viral
Bordetella Pertussis Influenza A Chlamydia trachomatis (CT) Methicillin-resistant

Staphylococcus aureus (MRSA)

Chlamydophila pneumoniae Influenza B Ureaplasma urealyticum (UU) Methicillin-sensitive

Staphylococcus aureus (MSSA)

Haemophilus influenzae Human adenovirus A/B/C/D/E Neisseria gonorrhoea (NG) Methicillin-resistant

coagulase-negative Staphylococci (MRCoNS)

Legionella pneumophila Human bocavirus 1/2/3 Mycoplasma genitalium (MG)
Moraxella catarrhalis Human coronavirus 229E/NL63 Trichomonas vaginalis (TV)
Mycoplasma pneumoniae Human coronavirus OC43/HKU1 Haemophilus ducreyi (HD)
Treponema pallidum (TP) Human enterovirus A/B/C Mycoplasma hominis (MH)
Bordetella parapetussis Human Metapneumovirus Streptococcus pneumoniae
Human parainfluenza virus 1 Herpes simplex Virus 1 (HSV-1)
Human parainfluenza virus 2 Herpes simplex Virus 2 (HSV-2)
Human parainfluenza virus 3
Human parainfluenza virus 4
Human respiratory syncytial virus A & B
Human rhinovirus A/B/C

Figure 1.

Lower and Upper Respiratory Tract Infections

The economic burden of respiratory illness in the UK costs a staggering £11 billion every year on lung disease alone1.  Lower respiratory tract infections (LRIs) are a substantial public health problem and a leading cause of illness and death in people of all ages2. It is estimated that LRI causes nearly 4 million deaths annually3.  Upper respiratory tract infections (URIs) account for an estimated 10 million outpatient appointments a year. Most of these appointments end with physicians needless writing of antibiotic prescriptions4.

Randox Biosciences offers a Respiratory Multiplex Array which rapidly detects and identifies the cause of 22 bacterial and viral pathogens helping to reduce the risk of antibiotic resistance.  Given that only bacterial infections can be treated with antibiotics, rapid diagnostic tests are urgently needed to distinguish between bacterial and viral infections.  This test will aid clinicians in their selection of the most appropriate antibiotic treatment for patients.  GPs would have additional efficiency savings for the NHS, by eliminating the need for lengthy microbiology lab tests and unnecessarily writing prescriptions.

The test is performed utilising our Biochip Technology which enables the simultaneous detection of multiple results from one patient sample. Biochip Technology powers Vivalytic which is the all-one solution for molecular diagnostics.

The main benefits of the Respiratory Multiplex Array are:

  • Turnaround time of 2 hours
  • Validated for sputum, lavage and nasopharyngeal samples
  • Panel includes viral and bacterial species to consolidate testing

Randox Biosciences are committed to the ongoing development of diagnostic tests, through our research into numerous disease areas, to improve health worldwide.

MEDICA World Forum for Medicine International Trade Fair

Randox Biosciences team will be attending Medica from the 18th – 21st of November 2019 at Messe Dusseldorf, Germany.  Stop by and say hello to some of our team members at our stand, and to learn more about our latest game-changing partnership with Bosch – the innovative Vivalytic platform!

Medica is at the forefront of new approaches in laboratory medicine, addressing the complexity of an evolving healthcare landscape.  This event attracts more than 5,100 exhibitors from 70 countries, engaging diverse professionals enabling them to discover new and innovative solutions to improving patient outcomes through effective lab testing, diagnosis and treatment.

To learn more about the Vivalytic offering, visit https://www.randoxbiosciences.com/clinical-laboratory/infectious-diseases/molecular-arrays/ or email us at info@randoxbiosciences.com

References:

  1. British Lung Foundation. (2019). Estimating the economic burden of respiratory illness in the UK. [online] Available at https://www.blf.org.uk/policy/economic-burden [Accessed 06 Nov. 2019].
  2. The Lancet Infectious Diseases. (2015). Estimates of the global, regional, and national morbidity, mortality, and aetiologies of lower respiratory tract infections in 195 countries: a systematic analysis for the Global Burden of Disease Study 2015. [online] Available at https://www.thelancet.com/journals/laninf/article/PIIS1473-3099(17)30396-1/fulltext [Accessed 29 Oct. 2019].
  3. Forum of International Respiratory Societies. The Global Impact of Respiratory Disease – Second Edition. Sheffield, European Respiratory Society, 2017.
  4. Thomas, M. and Bomar, P.   The National Centre for Biotechnology. Upper Respiratory Tract Infection. United States of America.

RESEARCH

BIOPHARMA

CLINICAL LAB

BIOREAGENTS


World Heart Day from Randox Biosciences

News       About Us        Randox Biosciences

29 September 2019

 

World Heart Day 2019

 

The World Heart Federation (WHF) is the acting global voice in leading the universal fight against cardiovascular disease (CVD).  Part of the WHF mission is to ensure heart health equity for everyone. They believe everybody is entitled to cardiovascular health and well-being through health promotion, access to prevention, control and management of CVD 1.

World Heart Day falls on the 29th September where people make a promise to promote and implement healthier lifestyles to maintain a happy and healthy heart, reducing the potential risks of heart disease and stroke.  CVD takes the lead being the number one cause of death world-wide 2 relating to all heart and circulatory diseases consisting of coronary heart disease, angina, heart attack, congenital heart disease, hypertension, stroke and vascular dementia 3.

According to the World Health Organisation2:

  • An estimated 17.9 million people died from CVD in 2016, representing 31% of all global deaths. Of these deaths, 85% were due to heart attack and stroke.
  • Out of the 17 million premature deaths (under the age of 70) due to noncommunicable diseases in 2015, 82% were in low- and middle-income countries, and 37% were caused by CVD.
  • Most cardiovascular diseases can be prevented by addressing behavioural risk factors such as tobacco use, unhealthy diet and alcohol abuse.
world-heart-day-2019

Cytokines have a central role within the immune system; they are a category of signalling molecules that mediate and regulate immunity, inflammation and hematopoiesis 4.  Cytokine and inflammatory mechanisms have major implications for the vascular system and can lead to CVD.

Cytokines exist in broad families that are structurally related but exhibit diverse function.  The major classes of cytokines include: pro- and anti-inflammatory cytokines, cytokines of neutrophil and eosinophil recruitment and activation, cytokines derived from T-helper (Th) and T-regulatory (Tregs) cells, and cytokines of T-cell recruitment and growth factors.

Randox offers a comprehensive menu of 26 cytokine, cytokine receptors and growth factors over four multi-analyte arrays.  Each cytokine assay is performed on biochip array technology with spatially discrete test regions containing antibodies specific to each of the analytes.  The combination of highly specific antibodies and advanced chemistries enables up to 12 cytokines and growth factors to be detected simultaneously in a single sample.

Cytokine Array I                                                            Cytokine Array III

  • Epidermal Growth Factor (EGF) –    Granulocyte Macrophage Colony Stimulating
  • Interferon-y –    Interleukin-5
  • Interleukin-1a –    Interleukin-15
  • Interleukin-1b –    Macrophage Inflammatory Protein-1a
  • Interleukin-2
  • Interleukin-4
  • Interleukin-6
  • Interleukin-8
  • Interleukin-10
  • Monocyte Chemotactic Protein-1
  • Tumour Necrosis Factor-a
  • Vascular Endothelial Growth Factor

Cytokine Array IV                                                                         Cytokine Array V

  • Matrix Metalloproteinase-9 –    Interleukin-3
  • Soluble IL-2 Receptor a –    Interleukin-7
  • Soluble IL-6 Receptor –    Interleukin-13
  • Soluble Tumour Necrosis Factor Receptor I –   Interleukin-12 p70
  • Soluble Tumour Necrosis Factor Receptor II –   Interleukin-23

Key Benefits of Randox Cytokine Arrays:

  • Multiplex testing from a single sample.
  • Suitable for human serum and plasma samples.
  • Small sample volume required.
  • Excellent analytical performance.
  • Fast throughput.
  • Applicable to fully automated and semi-automated Evidence analysers.

Randox manufacture the majority of assay raw materials in-house and can therefore take a more tailored approach, by adapting assays to the needs of your research project to best fit your individual requirements.

  1. https://www.world-heart-federation.org/
  2. https://www.who.int/news-room/fact-sheets/detail/cardiovascular-diseases-(cvds)
  3. https://www.bhf.org.uk/informationsupport/conditions/cardiovascular-disease
  4. https://www.sinobiological.com/cytokine-rerview-receptor-source-targets-main-function-disease-association-a-1310.html
  5. https://www.sciencedirect.com/topics/neuroscience/cytokines
Visit Randox Biosciences

Randox Biosciences Products and Services

RESEARCH

BIOPHARMA

CLINICAL LAB

BIOREAGENTS

Want to know more about Randox?

Contact us or visit our homepage to view more.


Metabolic Syndrome Arrays from Randox Biosciences

News       About Us        Randox Biosciences

17 September 2019

 

Metabolic Syndrome Arrays from Randox Biosciences

 

Metabolic syndrome is described as a combination of diabetes, high blood pressure and obesity. As result of three health conditions going on, it puts the individual at greater risk of developing coronary heart disease, stroke and many other risks. 1 As well as developing additional health conditions it can cause damage to the blood vessels, the blood pressure damages the blood vessels, the obesity causes a lot of strain on the blood vessels and the heart.2 Therefore, can result in serious long-term risks.

This serious health condition is very common, and studies state that it affects about 23% of adults. 3One in four adults in the UK are currently living with metabolic syndrome and often becomes more common with age2.

Usually it affects those who are overweight or considered obese, have an unbalanced diet containing high levels of sugar and fat and have high cholesterol and extremely high blood pressure2 therefore, the condition can be prevented by reducing the risks.

1 According to the NHS, metabolic syndrome occurs when a person has three or more of the following measurements:

-Abdominal obesity (Waist circumference of greater than 40 inches in men, and greater than 35 inches in women)

-Triglyceride level of 150 milligrams per deciliter of blood (mg/dL) or greater

– HDL cholesterol of less than 40 mg/dL in men or less than 50 mg/dL in women

– Systolic blood pressure (top number) of 130 millimeters of mercury (mm Hg) or greater, or diastolic blood pressure (bottom number) of 85 mm Hg or greater

There are many ways to prevent metabolic syndrome from developing, making lifestyle changes for example, ensuring their weight is healthy by increasing physical exercise, eating a well-balanced healthy diet containing whole grains, fruit, vegetables and fish and finally, visiting the GP to monitor and manage blood glucose, blood cholesterol and blood pressure, quit smoking and managing your stress.

Randox offers the Evidence Evolution including two Metabolic Syndrome Arrays which allows multiplex testing from a single sample allowing rapid turnaround time and are suitable for both serum and plasma samples.

 

 

metabolic syndrome

Metabolic Syndrome Array I

  • Ferritin
  • Interleukin-6 (IL-6)
  • Insulin
  • Leptin
  • Plasminogen Activator Inhibitor-1 (PAI-1)
  • Resistin

Metabolic Syndrome Array II

  • Adiponectin
  • C-reactive Protein (CRP)
  • Cystatin C

Want to know more about Randox?

Contact us or visit our homepage to view more.


RCLS and Drug Induced Kidney Injury Array (DIKI)

Drug Induced Kidney Injury (DIKI) panel is the latest innovative panel created by Randox Laboratories. It has been developed to identify four early stage markers of DIKI by screening for the biomarkers KIM-I, NGAL, Cystatin C, and Clusterin.

Drug induced nephrotoxicity is a common problem in clinical trials and clinical medicine and the incidence of drug-related acute kidney injury may be as high as 60%.1 With the success rates of phase I clinical trials sitting at just under 10% and 75 – 80 % of failures, from phase I – III, resulting from problems with efficacy and/or safety the need to improve patient safety and detect kidney injury as early as possible is vital.2

The novel Randox Drug Induced Kidney Injury Array (DIKI) test allows superior monitoring of nephrotoxicity for enhanced safety in drug development. The biomarkers have been identified as more sensitive than transitional testing methods to enhance accurate diagnosis of DIKI. The DIKI test will be able to identify the levels of toxicity present in the kidneys which is classified as one of the most common side effects of drug development trials.

In 2017, 75% to 80% of clinical trials failed due to unacceptable safety.2 The four biomarkers on the DIKI panel are recommended by the U.S. Food and Drug Administration and the European Medicines Agency. The biomarkers have been acknowledged as more sensitive than traditional creatinine and more specific for diagnosis and prediction monitoring. DIKI has a faster turn-around time than creatinine. The levels of serum creatinine take a lengthy 48 hours to rise in the urine of someone with Drug Induced Kidney Injury. Whereas the biomarkers, such as NGAL, on the new DIKI biochip from Randox, can be present in urine within hours following initial kidney insult. The Randox Biochip test is performed in under 3 hours. Randox Clinical Laboratory Services (RCLS) is a state of the art ISO 17025 accredited central laboratory with unrivalled facilities built upon Randox Laboratories experience and is Randox’s latest offering, dedicated to providing a clinical laboratory service designed to meet the time sensitive, bespoke requirements of clinical and research projects globally.

If you are facilitating a clinical trial and want to test for drug induced kidney injury RCLS is your out-sourcing testing solution. RCLS can assist you to ensure the toxicity and efficacy of your drug helping you to save money and time. With a greater understanding of human complexity, pharmaceutical companies are now focusing on developing safer drugs. The early detection of DIKI can reduce cost and time and will allow a safe drug in the market

If you are conducting a clinical trial or would like more information on RCLS contact info@rcls.com.

  1. https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4594214/
  2. https://blogs.sciencemag.org/pipeline/archives/2019/05/09/the-latest-on-drug-failure-and-approval-rates

 

 

 

 

 

 

 

 


DIKI: Drug Induced Kidney Injury Array from Randox Biosciences

Randox Biosciences introduces the innovative Randox Drug Induced Kidney Injury Array (DIKI). The new panels allow superior monitoring of nephrotoxicity for enhanced safety in drug development. It has been developed to identify four early stage markers of DIKI by screening for the biomarkers KIM-I, NGAL, Cystatin C, and Clusterin which have been identified as more sensitive than transitional testing methods to enhance accurate diagnosis of DIKI.

Our Biochip Array Technology enables multiplex immunoassay testing. The DIKI panel of 4 markers is combined on a single biochip, enabling simultaneous results from each patient sample, delivering:

  • Excellent inter-assay precision and required sensitivity
  • Superior specificity
  • Lower sample volume
  • Fast turnaround time
  • Safer drug development

 

With the number of hospitalised patients who develop a drug-induced renal problem due to the numbers of potent drugs have been added to the therapeutic arsenal in recent year1 – the DIKI can have a detrimental effect on a person’s health and wellbeing. Blakely stated that “drug-induced nephrotoxic contributes to 8 to 60% of all cases of AKI seen on the intensive care unit (ICU)”.2 Randox offers a 4-plex Drug Induced Kidney Injury test which detects early stage toxicity across the nephron, assisted through composite measurement. Earlier and more reliable detection of drug-induced kidney injury would improve clinical care and help to streamline drug-development. (Dieterle et al., 2010)3.

The poor sensitivity of serum creatinine for detecting and monitoring DIKI is well documented in academic journals. As a result, for early phase trials European Medicines Agency (EMA) and Food and Drug Administration (FDA) are encouraging the use of more novel urinary biomarkers alongside conventional safety monitoring. The new panel will be able to identify the levels of toxicity present in the kidneys which is classified as one of the most common side effects of drug development trials.

 

The new Randox Drug Induced Kidney Injury (DIKI) panel can help you conduct clinical trials safer and faster. For more information contact info@randoxbiosciences.com.

 

  1. https://www.ncbi.nlm.nih.gov/pubmed/2043284
  2. https://link.springer.com/chapter/10.1007/978-1-84628-937-8_3
  3. https://www.ncbi.nlm.nih.gov/pubmed/20458316

 

 

 

 

 

 

 

 


We Are Randox | Biosciences Placement Student Kathryn Wilson

For our 2018/19 placement students, their year with Randox is almost at an end.

To mark their time with us and wish them the best of luck with their future studies, we took the opportunity to speak with one of our placement students in the sales team, to give us an insight of her experience during a Randox placement year.

Meet Kathryn Wilson, Business Placement Sales Executive for Randox Biosciences.

 

Hi Kathryn, can you tell us a little bit about yourself?

I am a 21-year-old student studying Bsc Equine and Veterinary Bioscience at Aberystwyth University in Wales. In September 2018 I began working in the Biosciences division of Randox Laboratories, specifically working on the release of new molecular technologies for clinical diagnostics. As part of a newly formed sales team, my focus is on the diagnostics market in Ireland.

Why did you want to forge a career in sales?

Whilst studying my bio-veterinary degree my only focus had been on science, so I was keen to broaden my horizons and explore opportunities in a business role for a company involved in the life-sciences industry. Initially, I was tentative of a role in sales, but I knew it would be a good way to develop a broad knowledge of business and the industry, and develop new skills.

Why did you decide to take your placement year with Randox?

Randox was a perfect fit for me, as a global scientific company based in Northern Ireland. I was looking for a placement that would allow me to spend time at home before returning to Wales for university.

I was intrigued by their range of products and diverse market presence in industries such as pharmaceuticals, biotech, research and healthcare. It seemed like a good company to gain an insight into new research in a variety of career sectors.

Describe a typical day as a Business Placement Sales Executive.

My role has evolved as we have moved through the different stages of product development throughout the year. Initially, when I first joined the team, we were in the planning stage. This involved mapping potential contacts and key sites in Ireland, and developing a sales strategy.

As this is a new venture for Randox the role also involved educating the market on our technology and creating awareness in all potential points of sale. This educational aspect of my job involved regular trips and meetings across Ireland, and frequent UK team meetings to discuss market feedback and problem solve. It’s important that we have been able to adapt our sales strategy for the specific healthcare areas -from public to private and point-of-care to large laboratories. Coming into the final month of my placement we are now prepared for product release with confirmed validation studies and initial placements, and significant interest across Ireland.

What are some examples of the tasks and responsibilities of your role?

There has been a range of ongoing tasks throughout the year to facilitate a busy and growing division. I was given the responsibility of forecasting, logging orders and organising meetings, and have been involved in internal decision-making processes alongside management. I have also helped to manage the university contracts in Ireland for our lab equipment, reagents and outsourcing some testing for specific studies.

Before I finish my placement I’m researching the market for upcoming arrays for launch next year, and planning a final trip in Ireland.

What was the most exciting part of your placement with Randox Biosciences?

The opportunity to travel around Ireland and London has been excellent. To date I have participated in over 10 conferences on behalf of Randox. Highlights for me have been corporate hospitality with potential customers at the Randox Health Grand National, and presenting at the first Infectious Disease Forum for Randox, in front of representatives from microbiology sites across Ireland.

I was also trusted to conduct a trip on my own around Donegal and Sligo, coupled with a visit to our Donegal R&D site, Randox Teoranta in Dungloe, to learn about future veterinary arrays in development.

It has been a privilege to be able to work with such a diverse range of people – from the scientists developing the products, to the sales team specialising in markets across the globe.  There are so many different career paths here at Randox.

What has been the most challenging aspect of your time at Randox Biosciences?

I have been challenged to quickly adapt to the business environment and gain an in-depth understanding of the wide range of products. I have been pushed outside my comfort zone to discuss with customers, present to the team and take responsibility of the day-to-day tasks.

Knowing the new molecular diagnostics range, infectious disease panels, and competitors in the market well enough to be confident in front of potential customers on my own, has also been a challenge. Hard work at Randox is acknowledged however, and I was awarded runner-up Business Student of the Year.

What is the best thing about Randox and would you recommend this placement to other students?

The best thing about a placement with Randox is that you will be given as many opportunities as you are willing to take. They are very supportive and will push you as much as any other member of the team.

As a non-business student this year has given me a wealth of insight into the workings of a global company, as well as furthering my scientific knowledge and interests in many aspects of the industry.

I would recommend a Randox placement for students who are keen to gain as much experience as possible in a global company focused on new and exciting health research.

What are your goals for the future?

My experience at Randox has given me an excellent insight into the world of business in the biosciences industry, and has prepared me well to build a career in this exciting industry. I think that the experience gained through Randox will be applicable to many life sciences sectors which I would like to explore further.

Although I am not sure what the future may hold, in the shorter term I am looking forward to returning to finish my final year at Aberystwyth.

For more information about Randox Biosciences and what career opportunities we offer please contact info@randoxbiosciences.com

 

 

 

 

 

Placement student Kathryn Wilson

 

 

 

 

 

 

 

 

 


Randox Biosciences on Familial Hypercholesterolemia (FH)

What is Familial Hypercholesterolemia?

Familial Hypercholesterolemia (FH) is a genetic condition which is passed down from the parents’ genes. The British Heart Foundation has highlighted that FH is caused by a genetic mutation which means the liver is unable to remove excess ‘bad’ cholesterol (LDL), therefore, the LDL level in the blood remains high.2 Someone who suffers with FH would have high cholesterol from birth which can cause other health issues including heart and circulatory disease.

Heart UK states that more than 260,000 people in the UK may have FH. However, less than 10% of this number have been diagnosed and therefore, may not be aware of their condition.3 However, to date there are no clear symptoms if someone has FH until it is considered too late.

Familial Hypercholesterolemia (FH) symptoms

  • Swollen tendons/fatty lumps on the knuckles of your hands, at the back of your ankles and knees
  • Cholesterol deposits around the eye-lids (looks like pale and yellowish patches)
  • Grey-white cholesterol deposits around the corneas

If untreated, about 50% of men and 30% of women with FH will develop coronary heart disease by the time they are 55. More worryingly, on average in the UK, one person a day with FH has a heart attack. About a third of people don’t survive their first heart attack, and many who do survive will have damaged hearts.

The good news is that a 2008 study part-funded by the BHF found that people with FH who are diagnosed and treated before they develop heart disease generally live as long as people who don’t have FH. That’s why it is vitally important to get diagnosed as early as possible.

How Randox Biosciences can help

Randox Biosciences offers the Familial Hypercholesterolemia (FH) Arrays I & II to help encourage early diagnosis with rapid turnaround time. This allows results to be reported within days compared with NHS waiting lists which can be substantially longer.

Our two arrays are rapid, simple and accurate which enables the simultaneous detection of 40 FH-causing mutations (20 mutations per array) within the LDLR, ApoB and PCSK9 genes.

The mutational status can be determined rapidly from a single test, with a reduced need for confirmatory testing. Genetic analysis for FH mutations also allows for more accurate diagnosis compared to lipid profiling.

Familial Hypercholesterolemia (FH) Arrays I & II:

LDLR – 38 mutations

APOB – 1 mutation

PCSK9 – 1 mutation

Contact us

To find out more about the products that we offer, email us info@randoxbiosciences.com

 

 

 

 

 

 

 

 

 

 

 

 

 


Alzheimer’s Disease testing on the Randox Evidence Series

What is Alzheimer’s Disease?

Alzheimer’s Disease is a progressive disease and is one of the most common kinds of dementia.

Our brains are made up of billions of tiny nerve cells which connect to each other. However, if you have Alzheimer’s Disease the connections between the cells are lost, which results in the loss of brain tissue and causes nerve cells to die1.

The brain is responsible for sending signals between cells. Those who suffer with Alzheimer’s have less ‘chemical messengers’ in their brain, so the signals are not passed on as well1.

The statistics of those who suffer with dementia is increasingly high and the figure is set to rise in the foreseeable future. Over 850,000 people are living with dementia in the UK. Studies states that one million people in the UK will have dementia in 2025 and this will increase to two million by 2050.2

Symptoms of Alzheimer’s Disease

The symptoms of Alzheimer’s disease are divided into 3 main stages; early symptoms, middle-stage symptoms and later symptoms.

In the early stages, the main symptom of Alzheimer’s disease is memory lapses which can increase anxiety or agitation. In the early stages, it is often mistaken that the person is forgetful and aren’t aware they are suffering with Alzheimer’s. The typical signs are listed below:3

  • forget about recent conversations or events
  • misplace items
  • forget the names of places and objects
  • have trouble thinking of the right word
  • ask questions repetitively
  • show poor judgement
  • become less flexible and more hesitant to try new things

As the disease progresses, the symptoms will gradually get worse. Memory problems will get worse which can make it difficult for the person who suffers with the disease to remember names of their loved ones, recent events and even remember birthdays and anniversaries. More symptoms such as the following will develop;3

  • increasing confusion and disorientation – for example, getting lost, or wandering and not knowing what time of day it is
  • obsessive, repetitive or impulsive behaviour
  • delusions or feeling paranoid and suspicious about carers or family members
  • problems with speech or language
  • disturbed sleep
  • changes in mood
  • difficulty performing simple tasks and may need additional support e.g. help with eating, getting dressed etc.

In the later stages of Alzheimer’s disease, the symptoms become increasingly severe and patients will need full-time care and assistance. It will be problematic for the individual to do basic everyday tasks such as getting changed, going to the toilet, getting washed and feeding themselves. They could lose their speech, and have difficulty eating and swallowing which can result in severe weight loss.

How Randox can help

Randox want to help. Our Evidence immunoanalyser has revolutionised laboratory screening worldwide with the capability to process 3,960 tests per hour and a sample capacity of 360. We offer the Apolipoprotein E4 (ApoE4) Array for Alzheimer’s genetic risk assessment, which is a research use-only product developed for the Evidence Investigator. The ApoE4 Array measures both total ApoE protein levels and ApoE4 protein levels directly from plasma samples and using a ratio can classify patients as negative or positive for ApoE4. In turn we can then assess their risk for the development of Alzheimer’s disease.

For further information about the Randox Alzheimer’s Array or our Evidence Investigator, please email info@randoxbiosciences.com       

 

  1. https://www.alzheimers.org.uk/about-dementia/types-dementia/alzheimers-disease
  2. https://www.dementiastatistics.org/statistics-about-dementia/prevalence/
  3. https://www.nhs.uk/conditions/alzheimers-disease/symptoms/

 

 

 

 

 

 

 

 

 


Cystic Fibrosis Awareness Month at Randox Biosciences

May is National Cystic Fibrosis (CF) Awareness Month.  The purpose of having the awareness month is to educate and raise additional awareness to the public about the horrible disease and how it affects those who suffer. According to the Cystic Fibrosis Foundation, more than 30,000 people are living with cystic fibrosis. More than 75% of these people are diagnosed in their early childhood 1.

What is CF?

Cystic Fibrosis is a genetic, life-threatening disease which affects the respiratory and digestive system. A person with CF is born with the condition and therefore it is not possible to catch it from someone else.  The gene affected by CF controls the movement of salt and water in and out of cells, which results in a build-up of thick sticky mucus in the lungs, digestive system and other organs. This causes a wide range of challenging symptoms affecting the entire body.2

Symptoms of CF:

There are many symptoms to Cystic Fibrosis which can make life for someone who suffers with CF challenging. The build-up of sticky mucus in the lungs can make breathing difficult and clog up the pancreas which as a result can increase the risk of developing a lung infection or worse, death. This can make it difficult for those who have CF to absorb nutrients from food properly and therefore they must eat more calories to avoid malnutrition. Other symptoms include the following:3

Complications of CF:

3People with CF also have a higher risk of developing other conditions. These include:

  • weak and brittle bones (osteoporosis)– medicines called bisphosphonates can sometimes help
  • diabetes– insulin and a special diet may be needed to control blood sugar levels
  • nasal polyps and sinus infections – steroids, antihistamines, antibiotics or sinus flushes can help
  • liver problems
  • fertility problems – it’s possible for women with CF to have children, but men won’t be able to father a child without help from fertility specialists (see a doctor or fertility specialist for more advice)

 4There is no cure for CF, but with improved treatment and management people with Cystic Fibrosis are living longer. It’s thought that children born with CF nowadays are likely to live to an average age of over 50 years old.

 How we can help:

Randox Biosciences offer the Vivalytic with the Chronic Lung Disease cartridge, in combination with our intelligent Biochip Array Technology which detects 132 pathogens. The 132 species are simultaneously detected across this 320 Array including bacterial, viral, fungal targets and an antibiotic resistance marker from a single sputum sample!

For more information at info@randoxbiosciences.com or visit us at: wwww.randoxbiosciences.com

  1. https://www.cff.org/What-is-CF/About-Cystic-Fibrosis/
  2. https://www.blf.org.uk/support-for-you/cystic-fibrosis/what-is-it
  3. https://www.nhs.uk/conditions/cystic-fibrosis/
  4. https://www.nhsinform.scot/illnesses-and-conditions/lungs-and-airways/cystic-fibrosis

 

 

 

 

 

 

 

 

 

 

 

 


Improving stroke diagnoses with Randox Biosciences

A stroke can happen to anyone at any time. It is a serious life-threatening medical condition which occurs when the blood supply to part of the brain is cut off. It causes the brain cells to die resulting the abilities controlled by the brain such as memory and muscle control to become damaged. 1

According to the Stroke Association, strokes are considered the fourth biggest killer in the UK. There are more than 100,000 strokes each year which equals around one stroke every five minutes.2 Some people recover from the condition; however, two thirds of the survivors will have some sort of disability. 3

There are two mains types of strokes which are defined as “Ischemic strokes” and “Hemorrhagic stroke”.

Ischemic Stroke

Ischemic stroke is by far the most common kind of stroke, accounting for about 88% of all cases4. Ischemic strokes occur when there is an artery blockage which cuts off the blood supply to certain areas of the brain, which then results in brain cells being unable to make energy and dying. The arteries are vital for the brain as they bring fresh blood from the heart and lungs carrying oxygen and nutrients and taking away carbon dioxide and cellular waste. 4

Hemorrhagic Stroke

The hemorrhagic stroke is less common but is more severe as there is a higher risk of dying within the first three months. It is when a blood vessel ruptures causing a bleed inside the brain, resulting in the death of brain cells. They are responsible for 40% of all stroke deaths.5

Symptoms of Stroke

The most commons symptoms of a stroke are:

  • Weakness or numbness of the face, arm, or leg on one side of the body
  • Loss of vision or dimming in one or both eyes
  • Loss of speech, difficulty talking, or understanding what others are saying
  • Sudden, severe headache with no known cause
  • Loss of balance or unstable walking, usually combined with another symptom

Many risk factors can increase your chance of having a stroke. Some life style factors include being obese/overweight, not exercising enough, heavy drinking, use of illegal drug such as cocaine, cigarette smoking, high cholesterol, diabetes, disruptive sleeping pattern and family history of having stroke or heart attack.

Preventing Stroke

Up to 80% of strokes are preventable. 3 There are simple healthy lifestyle recommendations that could decrease your chances of developing a stroke in the future which include:

  • Controlling your blood pressures as it is one of the biggest preventions of developing a stroke.
  • Maintaining a healthy weight through a well-balanced diet involving rich fruit and vegetables as well as decreasing the amount of cholesterol, saturated fat and sodium intake.
  • Exercising regularly and staying within a good routine will also reduce your risk of having a stroke.
  • Quitting tobacco usage and decreasing alohcal intake will help as well as regular usage increases the risk of having high blood pressure.
  • Avoid taking illegal drugs such as cocaine as it reduces your blood flow which narrows the arteries.

Randox Biosciences offers a stroke array which works quickly to determine which type of stroke a person has experienced. Ischaemic stroke can be treated by thrombolysis and, with early usage, it can help limit stroke damage and disability.

However, inappropriate administration of thrombolytic therapy can cause serious adverse effects, including intracranial haemorrhage. Hence, there is an unmet clinical need for a rapid and highly sensitive testing that complements existing CT scanning approaches and facilitate the definitive identification of ischaemic stroke patients.

Randox’s innovative Biochip Array Technology enables simultaneous detection of eight stroke biomarkers from a single blood sample.

The eight biomarkers that can be detected in a single blood sample are:

  • Glutathione S-Transferase-Pi (GSTP-Pi)
  • Nucleoside Diphosphate Kinase A (NDKA)
  • Parkinson Protein 7 (PARK7)
  • Glial Fibrillary Acidic Protein (GFAP)
  • D-Dimer
  • Interleukin 6 (IL-6)
  • sNFR1
  • Heart Fatty Acid Binding Protein (H-FABP)

 

For more information email us at info@randoxbiosciences.com or visit our newly improved website: https://goo.gl/8qkYkg

 

  1. https://www.nhs.uk/conditions/stroke/
  2. https://www.stroke.org.uk/system/files/sotn_2018.pdf
  3. https://www.stroke.org/understand-stroke/what-is-stroke/stroke-facts/
  4. http://www.strokecenter.org/patients/about-stroke/ischemic-stroke/
  5. https://www.stroke.org/understand-stroke/what-is-stroke/hemorrhagic-stroke/

 

 

 

 

 

 

 

 

 

 


Request a meeting
×
Make an Enquiry - RX series
×
Make an Enquiry - Reagents
×
Kit Insert Request - Reagents
  • Signing up to our mailing list is quick and easy. We do not wish to send you any spam or junk email, therefore, you can expect to receive mailshots including new product launches and updates, market trends, attendance at key industry events and much more. Randox Laboratories promise never to sell your data and we will keep all your details, safe and secure. Read more in our Privacy Policy.
×
Kit Insert Request - Reagents
  • Signing up to our mailing list is quick and easy. We do not wish to send you any spam or junk email, therefore, you can expect to receive mailshots including new product launches and updates, market trends, attendance at key industry events and much more. Randox Laboratories promise never to sell your data and we will keep all your details, safe and secure. Read more in our Privacy Policy.
×
Make an Enquiry - Reagents
×
Make an Enquiry - Quality Control
×
Make an Enquiry - RIQAS
×
Make an Enquiry - RIQAS
×
Make an Enquiry - Quality Control
×
Make an Enquiry
  • Signing up to our mailing list is quick and easy. We do not wish to send you any spam or junk email, therefore, you can expect to receive mailshots including new product launches and updates, market trends, attendance at key industry events and much more. Randox Laboratories promise never to sell your data and we will keep all your details, safe and secure. Read more in our Privacy Policy.
×
Make an Enquiry - Biochip
  • This field is for validation purposes and should be left unchanged.
×
Make an Enquiry - Molecular
  • Signing up to our mailing list is quick and easy. We do not wish to send you any spam or junk email, therefore, you can expect to receive mailshots including new product launches and updates, market trends, attendance at key industry events and much more. Randox Laboratories promise never to sell your data and we will keep all your details, safe and secure. Read more in our Privacy Policy.
  • This field is for validation purposes and should be left unchanged.
×
Make an Enquiry - Future Diagnostics
×
Make an Enquiry - RX series (Product)
×
Make an Enquiry - Quality Control
  • Signing up to our mailing list is quick and easy. We do not wish to send you any spam or junk email, therefore, you can expect to receive mailshots including new product launches and updates, market trends, attendance at key industry events and much more. Randox Laboratories promise never to sell your data and we will keep all your details, safe and secure. Read more in our Privacy Policy.
×
Make an Enquiry - RIQAS
  • Signing up to our mailing list is quick and easy. We do not wish to send you any spam or junk email, therefore, you can expect to receive mailshots including new product launches and updates, market trends, attendance at key industry events and much more. Randox Laboratories promise never to sell your data and we will keep all your details, safe and secure. Read more in our Privacy Policy.
×
Make an Enquiry - Reagents
  • Signing up to our mailing list is quick and easy. We do not wish to send you any spam or junk email, therefore, you can expect to receive mailshots including new product launches and updates, market trends, attendance at key industry events and much more. Randox Laboratories promise never to sell your data and we will keep all your details, safe and secure. Read more in our Privacy Policy.
×
Por favor, introduzca sus datos para ver nuestro último seminario
×
Wyślij zapytanie
  • Rejestracja na naszej liście mailowej jest szybka i łatwa. Nie chcemy wysyłać e-maili zawierających spam lub wiadomości, które są automatycznie przekierowywane do kosza. W zawiązku z czym firma Randox deklaruje, że będzie wysyłac tylko informacje na temat nowych produktów,akutalizacji obecnych, trendów rynkowych, wydarzeń branżowych itp. Firma Randox Laboraotries obiecuje, że Państwa dane nie będą nigdzie przekazane, a przechowywanie owych danych będzie się odbywało z zachowaniem największego bezpieczeństwa. Prosimy o przeczytani naszje Polityki Prywatności.
×
Wyślij zapytanie
  • Rejestracja na naszej liście mailowej jest szybka i łatwa. Nie chcemy wysyłać e-maili zawierających spam lub wiadomości, które są automatycznie przekierowywane do kosza. W zawiązku z czym firma Randox deklaruje, że będzie wysyłac tylko informacje na temat nowych produktów,akutalizacji obecnych, trendów rynkowych, wydarzeń branżowych itp. Firma Randox Laboraotries obiecuje, że Państwa dane nie będą nigdzie przekazane, a przechowywanie owych danych będzie się odbywało z zachowaniem największego bezpieczeństwa. Prosimy o przeczytani naszje polityki prywatności.
×
Wyślij zapytanie
  • Rejestracja na naszej liście mailowej jest szybka i łatwa. Nie chcemy wysyłać e-maili zawierających spam lub wiadomości, które są automatycznie przekierowywane do kosza. W zawiązku z czym firma Randox deklaruje, że będzie wysyłac tylko informacje na temat nowych produktów,akutalizacji obecnych, trendów rynkowych, wydarzeń branżowych itp. Firma Randox Laboraotries obiecuje, że Państwa dane nie będą nigdzie przekazane, a przechowywanie owych danych będzie się odbywało z zachowaniem największego bezpieczeństwa. Prosimy o przeczytani naszje polityki prywatności.
×
Wyślij zapytanie
    Rejestracja na naszej liście mailowej jest szybka i łatwa. Nie chcemy wysyłać e-maili zawierających spam lub wiadomości, które są automatycznie przekierowywane do kosza. W zawiązku z czym firma Randox deklaruje, że będzie wysyłac tylko informacje na temat nowych produktów,akutalizacji obecnych, trendów rynkowych, wydarzeń branżowych itp. Firma Randox Laboraotries obiecuje, że Państwa dane nie będą nigdzie przekazane, a przechowywanie owych danych będzie się odbywało z zachowaniem największego bezpieczeństwa. Prosimy o przeczytani naszje polityki prywatności .
×
귀하의 문의 사항 제출
    Signing up to our mailing list is quick and easy. We do not wish to send you any spam or junk email, therefore, you can expect to receive mailshots including new product launches and updates, market trends, attendance at key industry events and much more. Randox Laboratories promise never to sell your data and we will keep all your details, safe and secure. Read more in our Privacy Policy.
×
귀하의 문의 사항 제출
×
귀하의 문의 사항 제출
×
귀하의 문의 사항 제출
×
Downloads
×
Contact

<p>

    Randox Clinical Chemistry Products Join the Randox Laboratories Mailing List * I would like to receive emails with new product releases and updates from Randox Laboratories, market trends, and more. I do not want to receive email marketing from Randox. Signing up to our mailing list is quick and easy. We do not want to send you any spam or junk emails, therefore, you can expect to receive mailshots including new product launches and updates, market trends, attendance at key industry events and much more. Randox Laboratories promises never to sell your data and we will keep all your details, safe and secure. Read more in our Privacy Policy.
</p>

×
Clinical Laboratory Survey